Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: Preliminary analysis

Neurogastroenterology and Motility

Volumn 23, Issue 10, 2011, Pages

  Camilleri, M ^a   Carlson, P ^a   Mckinzie, S ^a   Zucchelli, M ^c   D'Amato, M ^c   Busciglio, I ^a   Burton, D ^a   Zinsmeister, A R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Mayo Clinic   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

c11orf30; CDH1; ORMDL3; PRDM1; TLR9

Indexed keywords

INTERLEUKIN 6; TOLL LIKE RECEPTOR 9; UVOMORULIN; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADULT; ARTICLE; CELL FUNCTION; COLON MOTILITY; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENE; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INFECTION COMPLICATION; IRRITABLE COLON; LOWER FUNCTIONAL GASTROINTESTINAL DISORDER; MAJOR CLINICAL STUDY; MALE; MAST CELL; PARM1 GENE; PHENOTYPE; POSTINFECTIOUS INFLAMMATORY BOWEL DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80052832224     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01749.x     Document Type: Article

References (47)

1. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil 2005; 17: 311-6.
2. Camilleri M, McKinzie S, Busciglio I et al. Prospective study of motor, sensory, psychological and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-81.
3. Dorn SD, Palsson OS, Thiwan SI et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007; 56: 1202-9.
4. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
5. Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-94.
6. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-34.
7. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
8. Zaman MS, Robson KM, Lembo AJ. Overlap of irritable bowel syndrome (IBS) symptoms in patients with inflammatory bowel disease (IBD). Am J Gastroenterol 2002; 97: S284.
9. Saito YA, Mitra N, Mayer EA. Genetic approaches to functional gastrointestinal disorders. Gastroenterology 2010; 138: 1276-85.
10. Schreiber S, Rosenstiel P, Albrecht M et al. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 2005; 6: 376-88.
11. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-62.
12. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009; 58: 1152-67.
13. Aerssens J, Camilleri M, Talloen W et al. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 194-205.
14. Villani AC, Lemire M, Thabane M et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138: 1502-13.
15. UK IBD Genetics Consortium, Barrett JC, Lee JC, Lees CW et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009; 41: 1330-4.
16. Zucchelli M, Camilleri M, Nixon Andreasson A et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut 2011 [Epub ahead of print].
17. Sadik R, Stotzer PO, Simrén M, Abrahamsson H. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol Motil 2008; 20: 197-205.
18. Manabe N, Wong BS, Camilleri M et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22: 293-e82.
19. Deiteren A, Camilleri M, Bharucha AE et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010; 22: 415-23.
20. Barrett JC, Clayton DG, Concannon P et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009; 41: 703-7.
21. International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-62.
22. Talley NJ, Phillips SF, Wiltgen CM et al. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990; 65: 1456-79.
23. Camilleri M, Carlson P, Zinsmeister AR et al. Mitochondrial DNA and gastrointestinal motor and sensory functions in health and functional gastro-intestinal disorders. Am J Physiol 2009; 296: G510-6.
24. 2 adrenoceptor and serotonin-transporter polymorphisms associated with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53: 829-37.
25. Andresen V, Camilleri M, Kim HJ et al. Is there an association between GNβ3 C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 2006; 130: 1985-94.
26. Camilleri CE, Carlson PJ, Camilleri M et al. A study of candidate genotypes associated with dyspepsia in a US community. Am J Gastroenterol 2006; 101: 581-92.
27. Castillo EJ, Camilleri M, Locke GR III et al. A community based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004; 2: 985-96.
28. Camilleri M, Carlson P, Zinsmeister AR et al. Neuropeptide S receptor induces neuropeptide expression and associates with intermediate phenotypes of functional gastrointestinal disorders. Gastroenterology 2010; 138: 98-107.
29. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43-7.
30. Cremonini F, Mullan BP, Camilleri M et al. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002; 16: 1781-90.
31. Magnúsdóttir E, Kalachikov S, Mizukoshi K et al. Epidermal terminal differentiation depends on B lymphocyte-induced maturation protein-1. Proc Natl Acad Sci USA 2007; 104: 14988-93.
32. Ghadimi D, Vrese M, Heller KJ, Schrezenmeir J. Effect of natural commensal-origin DNA on toll-like receptor 9 (TLR9) signaling cascade, chemokine IL-8 expression, and barrier integritiy of polarized intestinal epithelial cells. Inflamm Bowel Dis 2010; 16: 410-27.
33. Hernandez-Lagunas L, Choi IF, Kaji T et al. Zebrafish narrowminded disrupts the transcription factor prdm1 and is required for neural crest and sensory neuron specification. Dev Biol 2005; 278: 347-57.
34. Halapi E, Gudbjartsson DF, Jonsdottir GM et al. A sequence variant on 17q21 is associated with age at onset and severity of asthma. Eur J Hum Genet 2010; 18: 902-8.
35. Camilleri M, Carlson P, McKinzie S et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility and sensation. Am J Physiol 2008; 294: G13-9.
36. Törkvist L, Halfvarson J, Ong RT et al. Analysis of 39 Crohn's disease risk loci in Swedish inflammatory bowel disease patients. Inflamm Bowel Dis 2010; 16: 907-9.
37. Esparza-Gordillo J, Weidinger S, Fölster-Holst R et al. A common variant on chromosome 11q13 is associated with atopic dermatitis. Nat Genet 2009; 41: 596-601.
38. Galanter J, Choudhry S, Eng C et al. ORMDL3 gene is associated with asthma in three ethnically diverse populations. Am J Respir Crit Care Med 2008; 177: 1194-200.
39. Halapi E, Gudbjartsson DF, Jonsdottir GM et al. A sequence variant on 17q21 is associated with age at onset and severity of asthma. Eur J Hum Genet 2010; 18: 902-8.
40. McGovern DP, Gardet A, Törkvist L et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 332-7.
41. Breslow DK, Collins SR, Bodenmiller B et al. Orm family proteins mediate sphingolipid homeostasis. Nature 2010; 463: 1048-53.
42. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
43. Tobin MC, Moparty B, Farhadi A, DeMeo MT, Bansal PJ, Keshavarzian A. Atopic irritable bowel syndrome: a novel subgroup of irritable bowel syndrome with allergic manifestations. Ann Allergy Asthma Immunol 2008; 100: 49-53.
44. Bikoff EK, Morgan MA, Robertson EJ. An expanding job description for Blimp-1/PRDM1. Curr Opin Genet Dev 2009; 19: 379-85.
45. Rossi CC, Kaji T, Artinger KB. Transcriptional control of Rohon-Beard sensory neuron development at the neural plate border. Dev Dyn 2009; 238: 931-43.
46. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
47. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41: 850-3.